PDCD1 and hepatocellular carcinoma: Thus blocking the PD-1/PD-L1 pathway could restore immune function, and based on numerous clinical trials, PD-1/PD-L1 checkpoint inhibitors have exhibited remarkable response rates in HCC patients [96].